Company OverviewEyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com.
Speaker BioPresident & CEO
Eyepoint Pharmaceuticals
Nancy Lurker, President and CEO of EyePoint Pharmaceuticals, has more than 30 years of experience in the pharmaceutical industry including drug delivery technology and diagnostics. She has a proven track record of maximizing the potential of new therapies and successfully implementing innovative US and global drug launches, having worked with start-ups and Fortune 500 companies. Lurker serves on many boards across public and private companies, and advocacy organizations. As a corporate leader, she is also extremely passionate about supporting the future of STEM.
